Various single nucleotide polymorphisms (SNPs) in lipid metabolism genes, such as patatin-like phospholipase domain-containing3 (PNPLA3), transmembrane 6 superfamily member 2 (TM6SF2), membrane-bound O-acyltransferase domain-containing 7 (MBOAT7), glucokinase regulator (GCKR) and hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13), have been linked to the onset and progression of NAFLD (17–21). This evidence concerns the gene TM6SF2 and metabolic dysfunction-associated steatotic liver disease.